Key points for patient discussions include: GLP-1 medications are FDA-approved only for type 2 diabetes and, for specific agents, chronic weight management Research on cognitive benefits is ongoing but not yet conclusive These medications have known side effects that require monitoring Dementia prevention involves multiple lifestyle and medical factors Women of childbearing potential should use effective contraception while taking GLP-1 medications, as safety in pregnancy is not established Patients should seek medical evaluation if they experience: New or worsening memory problems or confusion (which may warrant cognitive screening, laboratory tests including thyroid and vitamin B12, and possible referral to neurology) Severe gastrointestinal symptoms while taking GLP-1 medications Signs of dehydration (dizziness, decreased urination, dry mouth) Persistent abdominal pain that could indicate pancreatitis Neck mass or hoarseness (thyroid concerns) Sudden vision changes (potential retinopathy complications) Right upper quadrant pain, fever, or yellowing of skin/eyes (gallbladder or liver issues) Caregivers of individuals with established dementia should discuss with healthcare providers whether continuing or initiating GLP-1 therapy is appropriate, considering the person's ability to manage injections, report side effects, and maintain adequate nutrition
A treatment you can offer to your most reactive clients
Even though GSH is depleted within 3 hours (30 min in mice), NAC is completely protective as long as provided within 6 hours, which speaks to the importance of preventing necrosis by restoring GSH
They also found adverse outcomes for the embryos from the sperm exposed to ROS damage
Practical strategies for maintaining electrolytes on semaglutide include choosing the best foods to eat on semaglutide with an emphasis on mineral-dense options, and being deliberate about electrolyte supplementation on days when food intake is low
This study was supported in part by the Japan Society for the Promotion of Science (JSPS) KAKENHI (25293216 to M
